Combination Antifungal Therapy for Cryptococcal Meningitis
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Combination Antifungal Therapy for Cryptococcal MeningitisTo the Editor: In the trial of combination therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection, Day et al. (April 4 issue) 1 found a survival benefit associated with 2 weeks of therapy with amphotericin B and flucytosine as compared with amphotericin B monotherapy.The results of this trial reinforce the treatment combination as the standard per current guidelines. 2,3 In locations where amphotericin B therapy is not feasible, flucytosine is recommended in combination with fluconazole. 2-4However, the availability of flucytosine worldwide remains grossly inadequate.Flucytosine is currently unregistered and unavailable in most of Asia and Africa, where the disease burden is greatest. 5Even though flucytosine is a simple, orally administered, off-patent drug, only two manufacturers have been approved by the Food and Drug Administration: the originator company, Meda Pharmaceuticals, and the generic manufacturer, Sigmapharm Laboratories.The lack of data about disease burden, concerns regarding toxicity, and high drug costs due to a lack of competition have contributed to a market failure for flucytosine. 5Given the findings of Day et al., sustained efforts from governmental and international stakeholders are now required in order to urgently disseminate and implement World Health Organization (WHO) treatment guidelines, facilitate the registration of flucytosine, motivate generic-drug production, stimulate development of sustained-release formulations of flucytosine, and widen access to this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
Dromer, F., Mathoulin-Pélissier, S., Launay, O., Lortholary, O., & the French Cryptococcosis Study Group (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040021 · Cited by 374
Bicanic, T., Muzoora, C., Brouwer, A. E., Meintjes, G., Longley, N., Taseera, K., Rebe, K., Loyse, A., Jarvis, J., Bekker, L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604716 · Cited by 227
Self-citationJackson, A. T., Nussbaum, J. C., Phulusa, J., Namarika, D., Chikasema, M., Kanyemba, C., Jarvis, J. N., Jaffar, S., Hosseinipour, M. C., van der Horst, C., et al. (2012) · AIDS · doi:10.1097/qad.0b013e328354b419 · Cited by 86
Self-citation
Cited by
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“In the clinical setting, DAmB at a dose of 1 mg/kg/day in combination with 5FC has shown a mortality benefit over DAmB monotherapy and considered the standard of care for induction therapy of cryptococcal meningitis [84].”
Self-citationPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Jarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367
Self-citationParadoxical Immune Responses in Non-HIV Cryptococcal Meningitis
Panackal, A. A., Wuest, S. C., Lin, Y.-C., Wu, T., Zhang, N., Kosa, P., Komori, M., Blake, A., Browne, S. K., Rosen, L. B., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004884 · Cited by 162
Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84
“Induction therapy involves flucytosine and intravenous infusions of amphtotericin B (Loyse et al., 2013).”
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-06-27
- Volume
- 368
- Issue
- 26
- Pages
- 2522-2523
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3146780943
- Cited by
- 78
- References
- 5
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.